Status:
COMPLETED
Evaluate the Safety and Feasibility of tACS With the Miamind Neurostimulator in Healthy Participants
Lead Sponsor:
Bottneuro AG
Collaborating Sponsors:
Hemex AG
Conditions:
Healthy Participants
Healthy Population
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The present study aims to assess the safety and feasibility of repeated transcranial alternating current stimulation (tACS) by the Miamind Neurostimulator in a cohort of healthy participants. Based on...
Detailed Description
The pathological hallmarks of Alzheimer's Disease (AD) are extracellular amyloid-β (Aβ) plaques and intracellular neurofibrillary tangles of hyperphosphorylated tau deposition in the brain together wi...
Eligibility Criteria
Inclusion
- Participants who are overtly healthy as determined by medical evaluation including medical history and physical examination.
- Able and willing to provide voluntary written Informed Consent and sign the ICF to participate in the study prior to any study-related procedure.
- Must have the ability to comply with protocol-related tests, appointments, and procedures.
- Age over 18 years old.
- Knowledge of the German language (B1 or higher).
- No history of intellectual or learning disability; at least 8 grades of school.
- Non-disturbing hairstyle or headdress that enables electrode contact with the scalp judged by the investigator.
Exclusion
- Any acute or chronic disease/disorder (e.g., cerebral, psychiatric, cardiovascular, pulmonary, metabolic, skin etc.)
- History of traumatic brain injury or other diseases of the central nervous system.
- History of seizures, diagnosis of epilepsy, or abnormal (epileptiform) EEG, or immediate (1st-degree relative) family history of epilepsy.
- Diagnosis of substance abuse.
- Participant is under the influence of alcohol, and consumption of narcotics or benzodiazepines, or other sleeping medications prior to the procedure.
- All female participants that are not post-menopausal (defined as at least 12 months of spontaneous amenorrhea in women over 45 years old) or surgically sterile (e.g. bilateral tubal ligation, hysterectomy, bilateral oophorectomy) will be required to have a pregnancy test; any participant who is pregnant or breastfeeding will not be enrolled in the study.
- Metal implants (excluding dental fillings) or devices such as a pacemaker, cardioverter defibrillator, medication pump, nerve stimulator, Transcutaneous Electrical Nerve Stimulator (TENS) unit, ventriculoperitoneal shunt, and cochlear implant, unless cleared by the study MD.
- Contraindications for undergoing MRI.
- Ongoing participation in any other interventional clinical study with an investigational drug or another MD within the 30 days preceding and during the present investigation.
- Participants not suitable for the study based on a holistic consideration of the participant's history and the PI's medical expertise.
- No vulnerable subject is enrolled on this study
Key Trial Info
Start Date :
December 27 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 22 2024
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT05999916
Start Date
December 27 2023
End Date
March 22 2024
Last Update
August 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitätsspital Basel
Basel, Canton of Basel-City, Switzerland, 4031